Eric Lefkofsky Chicago’s new unicorn tech company

Three years ago, Eric Lefkofsky combined his expertise as an entrepreneur and knowledge in the technology industry to co-found Tempus, a new Chicago startup company. From first-hand experience, Eric learned that healthcare databases were small and disorganized. Having gained the expertise from he’s dealing with other technology platforms, he knew this was the platform that was needed to open a wider door for the healthcare industry. So Lefkofsky and his longtime friend and business partner Brad Keywell created Tempus Labs. Staff and teams of technology, data-science and cancer research experts were hired. Partnerships were developed with academic medical centers and cancer physicians.

The mission of Tempus was to innovate the way physicians thought and treated cancer. Their goal was to provide physicians a learning library of data from previous cancer patients. Data that not only contains patient history but analyzed data of physicians diagnose and treatments. Data that enables physicians to deliver an integrated treatment program that would be beneficial to patient outcome. Lefkofsky confirmed that Tempus has partnered with the University of Chicago, Rush University and Northwestern, as well as, over 50 other research hospitals, Cancer Institutes/Centers and drug companies across the United States.

In this short time, Tempus has grown to become one of Chicago’s top ten health tech companies. And after the latest round of funding in March 2018 this new startup is now the latest of Chicago’s “unicorn” tech company. In September of last year Tempus raised $70 million, and everyone thought it was an impressive feat. In March of this year the startup raised $80 million, raising the company’s value to $1.1 billion, bringing it to it’s “unicorn” status. This increase of highly needed investment money will cause a rolling effect of more hires of high tech personnel, increased research and more data collecting, to physicians more acutely customizing cancer treatment care. For cancer patients, it means instead of just focusing on their cancer, treatments are focused on them as a whole being.

Tempus has already aggregated the largest clinical cancer database, putting structure into the unstructured digital medical records systems. As Tempus continues to develop a model for collecting critic medical data and proving it can be done, the future looks bright for patients with other hard to treat diseases.

https://www.bloomberg.com/research/stocks/people/person.asp?personId=166953&privcapId=82311805

MedSpa Walden Cosmetic Surgery and Laser Center’s Dr. Jennifer Walden

Founder of MedSpa Walden Cosmetic Surgery and Laser Center, Dr. Jennifer Walden, is a world renown aesthetic plastic surgeon. In an industry that consists mostly of male doctors, Dr. Walden has made an impact and continues to leave her mark. Her practice, which she has relocated to her home state of Texas from New York where she received her specialized training, is made up of all women as well as catering to mainly female patients. The doctor and her staff pride themselves on the fact that they are a firm run by women, for women, in a mainly male field. It is not hard to guess that they enjoy the feeling of empowering other women.

Procedures offered at MedSpa Walden Cosmetic Surgery and Laser Center include but are not limited to face, breast, body, hair restoration, radio frequency treatments, injecatable treatments, skin treatments, femtouch laser, laser vaginal tightening, laser tattoo removal, non-invasive fat elimination, broadband light based treatments, and IV hydration therapy. Costs for procedures and treatments range from hundreds to thousands of dollars.

Dr. Walden studied as a plastic surgeon at Manhattan Eye, Ear, and Throat Hospital as well as Lenox Hill Hospital, both located in New York. Academic appointments after graduating as an accredited surgeon have included Instructor of Surgery at the New York University Langone Medical Center’s Department of Plastic Surgery and currently she is a Clinical Assistant Professor in Plastic Surgery at The University of Texas Southwestern.

Dr. Walden is on the Board of Directors for the American society for Aesthetic Plastic Surgery, and currently holds the position of Commissioner of Communications for organization as well as acting as their media spokesperson. She has been recognized as a Texas Super Doctor (2014), a Castle Connelly’s Top Doctors (2016), and one of 24 Best Beauty Surgeons in the United States by Harper’s Bazaar magazine (2014). She is also the author of several award-winning articles and research papers, and learn more about Dr. Walden.

Breakthrough Treatment for Multiple Sclerosis Discovered

Multiple Sclerosis is a disease that has the body’s immunity system attacking, and disabling the central nervous system (CNS). A clinical trial study named on the disease dubbed, HALT-MS, revealed that a high dosage of drugs that suppress the strength of the immunity system, coupled with a blood stem transplant, increase the chances of the sustained remission.

The NIAID, which is connected to the National Institute of Health sponsored the trial. It was coordinated by ITN which is funded by NIAID.

The trail study noted that sixty-nine percent of the people that participated in the pilot study did not experience progressive disability, new brain lesions or even relapse of the MS symptoms, five years after receiving the treatment.

The treatment is known as HDIT/HCT i.e. therapy that inhibits the activity in the immune system, and autologous cell transplanting in large doses. The study also observed that after going through the HDIT/HCT treatment, the participants did not need to continue taking any medication.

The trial treatment is centered on reducing the activity of the disease and eliminating the possibility of the CNS being disabled by this activity. This was done by the removal of the disease-inducing cells and rebooting the immune system by transplanting a participant’s blood-making stem cells.

The study has made tremendous success in stabilizing MS to date and reveal that HDIT/HCT can become a potential solution to people with relapsing-remitting multiple sclerosis.

Shiva Gopal Vasishta

Dr. Shiva Gopal Vasishta is well known for his specialty and contributions in Neurology globally. Dr. Gopal is also licensed to practice Psychiatry in Voorhees, New Jersey. He attained his medical degree from Government Medical College in 1979.

Dr. Shiva Gopal Vasishta went through his residency at Boston City Hospital and has over 40 years of medical excellence to date.

He currently operates his practice at Eastern Neurodiagnostic Associate. Dr. Shiva Gopal Vasishta is recognized for his affiliations with Kennedy Health System Cherry Hill where he is making significant contributions to the neurological field.